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ABSTRACT
Background    Suitable chemotherapy is needed to pro-
long the survival of patients with unresectable advanced 
or recurrent colorectal cancer. We scored the periodical 
changes of several prognostic markers during chemo-
therapy in patients with this type of cancer to discern the 
effectiveness of chemotherapy.  
Methods    Twenty consecutive patients with unresect-
able advanced or recurrent colorectal cancer were en-
rolled. All patients underwent combination chemother-
apy with oxaliplatin or irinotecan plus 5-fluorouracil/
leucovorin. Neutrophil/lymphocyte ratio (NLR), serum 
C-reactive protein (CRP), serum carcinoembryonic an-
tigen (CEA) and serum albumin (ALB) were compared 
between the two periods (before chemotherapy and 3 
months after it was started) in each patient. The scor-
ing system was as follows: points are added when a 
patient shows a decrease of NLR, CRP and CEA and an 
increase of ALB at 3 months after the start of chemo-
therapy with a possible final score of +4. On the other 
hand, points are reduced if a patient shows an elevation 
of NLR, CRP and CEA and a decrease of ALB at 3 
months after the start of chemotherapy with a possible 
final score of –4. 
Results    At 3 months after the start of first line chemo-
therapy, 13 patients showed positive scores but 7 patients 
showed zero or minus scores. According to our scoring 
system, we found the mean survival time (MST) of the 
13 patients with plus scores was 34 months and this 
was significantly better than that of the 7 patients who 
showed zero or minus scores (P = 0.0008). 
Conclusion    Our new scoring system is useful but 
when we find that first line chemotherapy is ineffective, 
we need to change it to second line chemotherapy as 
soon as possible. That may be the best treatment for pa-
tients with unresectable advanced or recurrent colorectal 
cancer. 
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5-Fluorouracil (5-FU) in combination with leucovorin 
(LV) (5-FU/LV) has been the standard systemic regi-
men for the treatment of unresectable advanced or re-
current colorectal cancer in most countries.1 Recently, 
combination chemotherapies with oxaliplatin plus 5-FU/
LV (FOLFOX) or irinotecan plus 5-FU/LV (FOLFIRI) 
have shown superior survival benefits when compared 
with 5-FU/LV, and led to a steady improvement in the 
median overall survival of these patients.2 Also, a mo-
lecular target drug administered as a first-line treatment 
showed efficacy, and these therapies are considered as 
the standard treatment.3 However, irrespective of the 
progress in chemotherapeutic drugs, the median overall 
survival was about 2 years in several pivotal phase III 
studies of chemotherapy for unresectable or metastatic 
colorectal cancer.4 In order to improve the survival of 
these patients, it is important to decide the effectiveness 
of first line chemotherapy. 
 Several prognostic markers for patients with gas-
trointestinal carcinomas have been used for evaluating 
patients’ response to chemotherapy. Neutrophil/lympho-
cyte ratio (NLR) of peripheral blood was detected as an 
immunological marker.5 Serum albumin (ALB) level 
and C-reactive protein (CRP) have been recognized as 
the prognostic nutritional marker and marker of inflam-
mation, respectively.6, 7 Also, serum carcinoembrionic 
antigen (CEA) level was a good indicator for progres-
sion of colorectal cancer.8 In the present study, we 
compared the periodical changes of these four markers 
(NLR, CRP, ALB and CEA) between the point before 
chemotherapy and at 3 months after the start of first line 
chemotherapy in consecutive patients with unresectable 
advanced or recurrent colorectal cancer. We scored in-
creases or decreases of these markers and investigated 
whether or not these scores expressed reactivity of pa-




Between April 2008 and June 2009, 20 patients were 
diagnosed with unresectable advanced or recurrent 
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Table 1. Patients’ characteristics
  Patients
Number  20
Age, mean (SD), yr  70.5 (7.9)
Male/female  13 /7
ECOG: PS 0/1  9 /11
Tumor: primary/recurrent  9 /11
Primary tumor: colon/rectum  13 /7
Site of metastasis Liver 9
 Lung 4
 Peritoneum 5
  Lymph node 2
First line chemotherapy FOLFOX/FOLFIRI 15 /5
 Bevacizumab plus 12
 ECOG: PS, Eastern Cooperative Oncology Group performance 
status; FOLFIRI, irinotecan plus 5-fluorouracil/ leucovorin; 
FOLFOX, oxaliplatin plus 5-5-fluorouracil/leucovorin.
colorectal cancer and were scheduled to undergo 
FOLFOX or FOLFIRI chemotherapy in our hospital. 
The Eastern Cooperative Oncology Group performance 
status of these patients was 0 or 1, and they had ad-
equate bone marrow (platelet count > 100,000/L, white 
blood cell count > 4000/L, granulocyte count > 1500/
L, haemoglobin > 10.0 mg/dL), renal (serum creatinine 
< 2.0 mg/dL), and hepatic (serum bilirubin < 2.0 mg/dL) 
functions. Fifteen patients underwent FOLFOX treat-
ment, but 5 patients wanted FOLFIRI treatment instead. 
Bevacizumab was administered to 12 patients (FOLFOX, 
9 patients and FOLFIRI, 3 patients). The Ethics Com-
mittee of Tottori University (approval number 1223) 
approved this study in 2008. Informed consent was ob-
tained from all 20 patients. They were followed up until 
April 2013 and their details are shown in Table 1. 
 
Blood samples
Blood samples were taken from each patient before start 
of the first line chemotherapy and at 3 months after the 
start of chemotherapy. NLR, serum ALB, CRP and 
CEA levels were compared between the two periods.
 
Scoring system
At 3 months after the start of chemotherapy, the NLR, 
CRP, CEA and ALB levels were compared with those 
of before chemotherapy in each patient. Scoring was as 
follows: decreased NLR, +1; increased NLR, –1; de-
creased CRP, +1; increased CRP, –1; decreased CEA, 
+1; increased CEA, –1; increased ALB, +1; decreased 
ALB, –1. In cases with a decrease of NLR, CRP and 
CEA and with an elevation of ALB at 3 months after 
the start of chemotherapy, we gave a score of +4. On the 
other hand, when we found cases with an elevation of 
NLR, CRP and CEA and with a decrease of ALB at 3 
months after the start of chemotherapy, we gave a –4. If 
the patient showed a decrease of NLR and CRP, and an 
increase of CEA and ALB at 3 months after the start of 
chemotherapy, his final score was +2. A “0 score” was 
given when we found equal levels of NLR, CRP, CEA 
and ALB before and after chemotherapy.
 
Statistics 
The chi-square test for independence, Fisher’s exact 
probability test, and the Mann-Whitney U test were used 
to compare the differences between the two parameters. 
Spearman’s rank correlation coefficient was used to as-
sess the correlation between the two parameters. Surviv-
al rates of the two groups were estimated by the Kaplan-
Meier method, and the statistical differences between 
survival curves were examined by the log-rank test. A P 
value of < 0.05 was regarded as statistically significant. 
 
RESULTS
All patients were followed up at our hospital. The me-
dian follow-up period of the 20 patients was 28.3 months 
(range, 5–63 months). During the follow-up period, 17 
patients died due to disease progression. The mean pre-
treatment levels of NLR, CRP, CEA and ALB were 2.7, 
1.1 mg/dL, 237.7 ng/mL and 3.8 g/dL. And the mean 
post-treatment levels were 2.0, 0.9 mg/dL, 153.6 ng/mL 
and 3.7 g/dL each. At 3 months after the start of first 
line chemotherapy, decreased NLR was detected in 14, 
decreased CRP was detected in 15, decreased CEA was 
detected in 15, and increased ALB was detected in 8 pa-
tients. 
 According to our scoring system, we found that 
6 were +4, 2 were +3, 3 were +2 and 2 patients were 
+1. However, 3 were 0 and 4 patients were –4 and –3. 
The mean survival time (MST) of 13 patients with plus 
Fig. 1. The survival curve of 13 patients with plus scores (solid 
line) is significantly better than that of 7 patients with minus or 
zero scores (dotted line). The difference is statistically significant 
(P = 0.0008). 
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Table 2. Prognostic analysis of 20 patients
 Median  n MST  P
 (%)  (mo)
  High 10 34
NLR decrease ratio 34.3    0.3069
  Low 10 19 
  High 10 24
CRP decrease ratio 34.9    0.9685
  Low 10 20
  High 10 34
CEA decrease ratio 47.4    0.0119
  Low 10 19
  High 10 30
ALB increase ratio –2.5    0.3873
  Low 10 23
 ALB, albumin; CEA, carcinoembryonic antigen; CRP, C-reactive 
protein; MST, mean survival time; NLR, neutrophil/lymphocyte 
ratio.
Fig. 2. There is a significantly positive correlation between CEA 
decreasing ratios (X axis) and NLR decreasing ratios (Y axis,  = 
0.651, P = 0.0046). CEA, carcinoembryonic antigen; NLR, neu-
trophil/lymphocyte ratio. 
scores was 34 months and this was significantly better 
than that of the 7 patients who showed zero or minus (19 
months, Fig. 1, P = 0.0008). 
 We calculated the decrease ratio [(pre – post)/pre  
100%] of NLR, CRP and CEA in each case and calcu-
lated the increase ratio [(post – pre)/pre  100%] of ALB 
in each case. We found strong correlations among these 
ratios [NLR and CRP:  = 0.615, P = 0.0073; NLR and 
CEA: ρ = 0.651, P = 0.0046 (Fig. 2); NLR and ALB:  = 
0.59, P = 0.0102; CRP and CEA:  = 0.497, P = 0.0303; 
CRP and ALB:  = 0.614, P = 0.0075 and CEA and 
ALB:  = 0.483, P = 0.0354].  
 We investigated the prognostic strength of each 
parameter. Then, we divided the patients into two sub-
groups according to the median levels of each param-
eter. Table 2 shows that the CEA decrease ratio was a 
good parameter of prognosis of patients with unresect-




For patients with unresectable advanced or recurrent 
colorectal cancer, it is important to continue effec-
tive chemotherapy for as long as possible. FOLFOX or 
FOLFOX plus bevacizumab has been recognized as 
a good first line chemotherapy for these patients,9 but 
in cases where first line chemotherapy is ineffective, 
we should change the treatment to second line chemo-
therapy as soon as possible. To find out whether first 
line chemotherapy is effective or not, we looked for suit-
able markers. Another point is that several parameters 
have been reported as useful markers to determine the 
effectiveness of chemotherapeutic drugs in advanced 
colorectal cancer.10, 11, 12 But when we use these mark-
ers, we need to do special immunostaining of resected 
specimens or bioptic samples, or we need to check the 
periodical changes of tumors by using an imaging ana-
lyzer. These methods may be useful, but it will take lots 
of time and money and/or require special techniques to 
perform these methods. 
 It is well known that circulating lymphocytes play 
an important immunological role in various carci-
nomas.13, 14 In addition, a strong correlation between 
cancer progression and lymphopaenia was detected in 
patients with clear cell renal carcinoma.14, 15 Lissoni et 
al. reported that independently of tumor histotype and 
chemotherapeutic regimen, lymphocytosis occurred in 
patients who achieved an objective tumor regression in 
response to chemotherapy, and the mean lymphocyte 
count observed at the end of the chemotherapeutic treat-
ment was significantly higher than that seen before the 
onset of treatment.16 They added that the mean lympho-
cyte count decreased with chemotherapy in patients with 
tumor progression. Based on this finding, we invented a 
new scoring system using NLR, CRP, CEA and ALB to 
decide the effectiveness of first line chemotherapy. This 
system is very simple and we can use this system with-
out special techniques.  
 Even though the total number of our investigated 
cases was small, we found that this scoring system accu-
rately predicted the prognosis of patients with unresect-
able advanced or recurrent colorectal cancer during che-
motherapy in our study. Specifically, CEA should be a 
good indicator of tumor progression, but many colorec-
tal tumors that did not express CEA elevation according 
to the tumor progression have been reported.17, 18 In such 
cases, peripheral lymphocytes counts, CRP and serum 
ALB should be good indicators. In this paper, we dis-
cuss the usefulness of a scoring system as a parameter 
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of effectiveness of first line chemotherapy for colorectal 
cancer. For all patients, peripheral blood samples were 
checked every month and these data are what our sys-
tem used. NLR, serum ALB, CRP and CEA levels were 
compared between the two periods (before the start of 
first line chemotherapy and at 3 months after the start 
of chemotherapy). Usually, the response assessment has 
been checked every 2 or 3 months during chemotherapy 
in advanced colorectal cancers.19 Our scoring system 
may indicate total patient conditions including immu-
nological aspects of patients or tumor regression dur-
ing chemotherapy. However, the prognostic differences 
among the patients who showed scores of +4, +3, +2, +1, 
0, –1, –2, –3 and –4 were unclear. In order to clarify this, 
we need to investigate our scoring system with a larger 
scale study of colorectal cancer patients. 
 In conclusion, when we suspect that first line che-
motherapy will be ineffective for patients, our scoring 
system can help us to decide to change to the second line 
chemotherapy as soon as possible. That may be the best 
treatment for patients with unresectable advanced or re-
current colorectal cancer undergoing chemotherapy. 
The authors declare no conflict of interest.
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